HIV Vaccine Peptide Constructs Stabilizing gp120-gp41 Complexes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mechanisms to address HIV infection and AIDS are inadequate in targeting chronic immune stimulation induced by HIV-1, particularly the C5 domain of gp120, which is immunodominant and conserved across multiple subtypes, leading to unknown immune activation mechanisms and ineffective drug and diagnostic/prognostic means.
Innovation Solution
Development of peptide constructs and antigens combining amino acid sequences from the C5 domain of gp120 with transmembrane domain sequences of gp41, which are recognized by antibodies from long-term non-progressing HIV-infected individuals, stabilizing specific conformations to prevent immune activation, and used as vaccine agents or diagnostic tools.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If conventional HIV treatment approaches are used, then viral load reduction is achieved, but chronic immune stimulation induced by C5 domain remains unaddressed
Solution Approach 1:
The invention extracts and isolates the C5 domain peptide sequence from the complete gp120 protein structure. By focusing specifically on the C5 domain (amino acid residues 499-511), the treatment targets the specific region responsible for immune activation and HLA-like activity, separating it from other functional domains of gp120 that may have different roles in viral infection.
Solution Approach 2:
The C5 domain peptide acts as an intermediary substance that mimics the structure and function of human HLA molecules. This intermediary can bind to T-cell receptors and modulate immune responses without requiring the complete viral protein, thereby intervening in the pathological immune activation process caused by HIV.
2Reliability
If antibodies to C5 domain are developed, then immune activation is reduced and disease progression slows, but the mechanisms of C5-associated immune activation remain unknown
Solution Approach 1:
The invention creates synthetic copies of the C5 domain peptide sequence (amino acid residues 499-511: AKRRVVQREKR with variations at positions 500 and 507) that replicate the structure recognized by protective antibodies. These peptide copies can be produced recombinantly or synthetically, providing a tool to study antibody binding and immune activation mechanisms without requiring the complete native protein.
3Object-affected harmful factors
If C5 domain is targeted for therapy, then immune activation may be blocked, but the domain shows substantial variation at positions 500 and 507 across viral clades
Solution Approach 1:
The invention focuses therapeutic intervention on the highly conserved C5 domain region (amino acid residues 499-511) while acknowledging that positions 500 and 507 show clade-specific variation. By designing peptides that can accommodate or target the conserved core sequence, the treatment maintains local effectiveness at the critical immune activation site while the variations at specific positions are managed through multi-epitope or consensus sequence approaches.
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
Disclosed is a method for treatment of HIV related diseases comprising targeting complexes between on the one hand the C5 domain of gpl20 and on the other hand gp41 or the C2 domain of gpl20. The complexes may be stabilised by administering compounds, such as antibodies, capable of directly interacting with and stabilising the complex, or by immunizing with C5 and gp41/C2 derived material so as to induce antibodies that bind to and stabilise the complex.